Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis

Company Overview

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease. The company’s research is centered on amyloid-beta oligomers, toxic protein assemblies that Acumen believes play a key role in the development and progression of neurodegenerative disease.

Acumen’s lead product candidate is sabirnetug, formerly known as ACU193, an investigational monoclonal antibody designed to selectively target amyloid-beta oligomers while avoiding much of the amyloid plaque targeted by some other Alzheimer’s therapies. The candidate is being evaluated in clinical studies for its potential to slow or modify disease progression in people with early Alzheimer’s disease.

Founded in 1996 and headquartered in Charlottesville, Virginia, Acumen conducts its research and clinical development activities primarily in the United States and through international clinical-trial networks. The company does not currently market an approved commercial product, and its development programs remain subject to clinical, regulatory and other risks.

Key Stats

• Today's Range: $2.02 to $2.10
• 50-Day Range: $2.04 to $3.19
• 52-Week Range: $1.50 to $3.60
• Volume: 580,519 shs
• Average Volume: 526,438 shs
• Market Capitalization: $147.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Acumen Pharmaceuticals Stock Analysis - MarketRank™

Acumen Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 480th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Acumen Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Acumen Pharmaceuticals has a consensus price target of $7.00, representing about 243.1% upside from its current price of $2.04.

Amount of Analyst Coverage

Acumen Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.60) to ($1.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acumen Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acumen Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acumen Pharmaceuticals has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.32% of the float of Acumen Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Acumen Pharmaceuticals has a short interest ratio ("days to cover") of 8.16.

Change versus previous month

Short interest in Acumen Pharmaceuticals has recently decreased by 11.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acumen Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Acumen Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for ABOS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.20% of the stock of Acumen Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ABOS
• CIK: 1576885
• Web: www.acumenpharm.com
• Phone: 434-297-1000
• Fax: N/A
• Employees: 61
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Acumen Pharmaceuticals: $7.00
• High Price Target: $8.00
• Low Price Target: $5.00
• Potential Upside/Downside: +243.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$121.33 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -136.27%
• Return on Assets: -81.64%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 2.47
• Quick Ratio: 2.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.16 per share
• Price / Book: 1.76

Miscellaneous

• Outstanding Shares: 72,320,000
• Free Float: 64,941,000
• Market Cap: $147.53 million
• Optionable: Optionable
• Beta: 0.33